Juergen Moll
Boehringer Ingelheim (Austria)(AT)
Publications by Year
Research Areas
Microtubule and mitosis dynamics, Cancer-related Molecular Pathways, Ubiquitin and proteasome pathways, Cancer Immunotherapy and Biomarkers, Mitochondrial Function and Pathology
Most-Cited Works
- → Potent and Selective Aurora Inhibitors Identified by the Expansion of a Novel Scaffold for Protein Kinase Inhibition(2005)143 cited
- → The glomerulosclerosis gene Mpv17 encodes a peroxisomal protein producing reactive oxygen species.(1994)113 cited
- → Catecholic Flavonoids Acting as Telomerase Inhibitors(2004)56 cited
- → Thieno[3,2-c]pyrazoles: A novel class of Aurora inhibitors with favorable antitumor activity(2010)28 cited
- → Abstract PL06-01: Discovery of BI-3406: A potent and selective SOS1::KRAS inhibitor opens a new approach for treating KRAS-driven tumors(2019)5 cited
- → The privilege of expressing CD44v - used by immune cells, misused by tumour cells(1996)1 cited
- → Small Interfering Ribonucleic Acids(2007)1 cited
- → Abstract C133: Effective targeting of KRAS-driven tumors by the first-in-class, orally bioavailable SOS1::KRAS inhibitor BI-3406(2019)1 cited
- → Abstract 2330: BI5: a novel SMAC mimetic that triggers tumor cell death and potentiates PD-1 mediated cancer therapy(2017)1 cited
- → 363 POSTER In vitro and in vivo molecular characterization of PHA-739358, an inhibitor of Aurora kinases(2006)